A debt funding round has pulled in $4.8 million for Xlumena, maker of the Navix pancreatic cyst-access system already cleared by the FDA. The Mountain View, Calif.-based endoscopy device firm is also finalizing clinical studies of its Axios stent and delivery device to back its 510(k) application for the product.

Related Summaries